Recently, lapatinib has been shown to exert beneficial effects in combination with capecitabine in patients with HER2-positive advanced breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab [9]. Here, ERBB2 is linked to breast carcinoma.